Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administration
Clemens Muehlan, Sander Brooks, Rob Zuiker, et al.
European Neuropsychopharmacology (2019) Vol. 29, Iss. 7, pp. 847-857
Closed Access | Times Cited: 49

Showing 1-25 of 49 citing articles:

Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials
Emmanuel Mignot, David Mayleben, Ingo Fietze, et al.
The Lancet Neurology (2022) Vol. 21, Iss. 2, pp. 125-139
Closed Access | Times Cited: 145
Hypocretins (orexins): The ultimate translational neuropeptides
Laura H. Jacobson, Daniël Hoyer, Luı́s de Lecea
Journal of Internal Medicine (2022) Vol. 291, Iss. 5, pp. 533-556
Closed Access | Times Cited: 71
Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders
Clemens Muehlan, Cédric Vaillant, Isabelle Zenklusen, et al.
Expert Opinion on Drug Metabolism & Toxicology (2020) Vol. 16, Iss. 11, pp. 1063-1078
Closed Access | Times Cited: 70
Daridorexant: First Approval
Anthony Markham
Drugs (2022) Vol. 82, Iss. 5, pp. 601-607
Open Access | Times Cited: 56
Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder
Dieter Kunz, Yves Dauvilliers, Heike Beneš, et al.
CNS Drugs (2022) Vol. 37, Iss. 1, pp. 93-106
Open Access | Times Cited: 52
Advances in the Treatment of Chronic Insomnia: A Narrative Review of New Nonpharmacologic and Pharmacologic Therapies
Russell Rosenberg, Leslie Citrome, Christopher L. Drake
Neuropsychiatric Disease and Treatment (2021) Vol. Volume 17, pp. 2549-2566
Open Access | Times Cited: 47
Efficacy and Safety of Daridorexant in Older and Younger Adults with Insomnia Disorder: A Secondary Analysis of a Randomised Placebo-Controlled Trial
Ingo Fietze, Claudio L. Bassetti, David Mayleben, et al.
Drugs & Aging (2022) Vol. 39, Iss. 10, pp. 795-810
Open Access | Times Cited: 32
A Phase 1B Trial in GBA1‐Associated Parkinson's Disease of BIA‐28‐6156, a Glucocerebrosidase Activator
Jonas M. den Heijer, Annelieke C. Kruithof, Matthijs Moerland, et al.
Movement Disorders (2023) Vol. 38, Iss. 7, pp. 1197-1208
Open Access | Times Cited: 18
Emerging and upcoming therapies in insomnia
W.-H. Kim, Ho-Sook Kim
Translational and Clinical Pharmacology (2024) Vol. 32, Iss. 1, pp. 1-1
Open Access | Times Cited: 6
A randomized single and multiple ascending dose study in healthy volunteers of LTI‐291, a centrally penetrant glucocerebrosidase activator
Jonas M. den Heijer, Annelieke C. Kruithof, Guido van Amerongen, et al.
British Journal of Clinical Pharmacology (2021) Vol. 87, Iss. 9, pp. 3561-3573
Open Access | Times Cited: 40
A randomised crossover trial of daridorexant for the treatment of chronic insomnia and nocturia
Katharina Lederer, Heike Beneš, Alan Fine, et al.
Journal of Sleep Research (2025)
Open Access
Effect of the new dual orexin receptor antagonist daridorexant on nighttime respiratory function and sleep in patients with mild and moderate obstructive sleep apnea
Marie‐Laure Boof, Jasper Dingemanse, Katharina Lederer, et al.
SLEEP (2020) Vol. 44, Iss. 6
Open Access | Times Cited: 33
Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem
Mike Ufer, Debra Kelsh, Kerri A. Schoedel, et al.
SLEEP (2021) Vol. 45, Iss. 3
Open Access | Times Cited: 31
Driving Performance after Bedtime Administration of Daridorexant, Assessed in a Sensitive Simulator
Clemens Muehlan, Sander Brooks, Cédric Vaillant, et al.
Clinical Pharmacology & Therapeutics (2022) Vol. 111, Iss. 6, pp. 1334-1342
Open Access | Times Cited: 20
Daridorexant for the treatment of insomnia disorder: A systematic review and meta-analysis of randomized controlled trials
Feiyu Jiang, Hang Li, Yanting Chen, et al.
Medicine (2023) Vol. 102, Iss. 7, pp. e32754-e32754
Open Access | Times Cited: 12
Number, Duration, and Distribution of Wake Bouts in Patients with Insomnia Disorder: Effect of Daridorexant and Zolpidem
Tobias Di Marco, Thomas E. Scammell, Michael Meinel, et al.
CNS Drugs (2023) Vol. 37, Iss. 7, pp. 639-653
Open Access | Times Cited: 10
Daridorexant treatment for chronic insomnia: a real-world retrospective single-center study
Mariana Fernandes, Fabio Placidi, Nicola Biagio Mercuri, et al.
Neurological Sciences (2024) Vol. 45, Iss. 7, pp. 3443-3448
Open Access | Times Cited: 3
Clinical pharmacology of the dual orexin receptor antagonist ACT-541468 in elderly subjects: Exploration of pharmacokinetics, pharmacodynamics and tolerability following single-dose morning and repeated-dose evening administration
Clemens Muehlan, Margaux Boehler, Sander Brooks, et al.
Journal of Psychopharmacology (2019) Vol. 34, Iss. 3, pp. 326-335
Closed Access | Times Cited: 29
Multiple-dose clinical pharmacology of the selective orexin-1 receptor antagonist ACT-539313
Priska Kaufmann, Marion Anliker‐Ort, Georg Golor, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2020) Vol. 108, pp. 110166-110166
Closed Access | Times Cited: 24
Daridorexant for the Treatment of Insomnia
Christopher L. Robinson, Rajesh Supra, Evan Downs, et al.
Health psychology research (2022) Vol. 10, Iss. 3
Open Access | Times Cited: 15
Daridorexant in Insomnia Disorder: A Profile of Its Use
Tina Nie, Hannah A. Blair
CNS Drugs (2023) Vol. 37, Iss. 3, pp. 267-274
Open Access | Times Cited: 8
Efficacy, safety, and tolerability of nivasorexant in adults with binge‐eating disorder: A randomized, Phase II proof of concept trial
Susan L. McElroy, Preciosa M. Coloma, Benjamin Berger, et al.
International Journal of Eating Disorders (2023) Vol. 56, Iss. 11, pp. 2120-2130
Open Access | Times Cited: 8
Effect of the novel dual orexin receptor antagonist daridorexant on night‐time respiratory function and sleep in patients with moderate chronic obstructive pulmonary disease
Marie‐Laure Boof, Jasper Dingemanse, Mareile Brunke, et al.
Journal of Sleep Research (2021) Vol. 30, Iss. 4
Closed Access | Times Cited: 19
Effect of Daridorexant on the Pharmacokinetics of Midazolam, and on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects
Isabelle Zenklusen, Jasper Dingemanse, Christian Reh, et al.
Drugs in R&D (2024) Vol. 24, Iss. 1, pp. 97-108
Open Access | Times Cited: 2
Preclinical metabolism and the disposition of vornorexant/TS‐142, a novel dual orexin 1/2 receptor antagonist for the treatment of insomnia
Yoshihiro Konno, Shunsuke Kamigaso, Hidetoh Toki, et al.
Pharmacology Research & Perspectives (2024) Vol. 12, Iss. 2
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top